Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma

Yair Herishanu, Chava Perry, Rony Braunstein, Ur Metser, Odelia Goor, Ori Rogowski, Shlomo Berliner, Aaron Polliack, Elizabeth Naparstek

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In the light of an emerging role for early-mid treatment 18 F-deoxyfluoroglucose positron emission tomography (FDG-PET) as an important prognostic indicator in aggressive non-Hodgkin's lymphoma (NHL), we attempted to determine whether a simple parameter, such as the early-mid treatment CRP (C-reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL. Patients and methods: Serum CRP levels were monitored in 55 patients with aggressive NHL. The lowest value of the early mid-term CRP levels recorded was compared with the interim PET-CT results, as well as with the clinical course and eventual outcome. Results: During chemotherapy, the lowest value of early-mid treatment CRP levels significantly predicted the results of the interim FDG-PET (P = 0.04 with an odds ratio of 1.13). Patients who did not achieve an early-mid treatment CRP level of <5 mg/L, had a shorter time to disease progression or relapse (P = 0.001) as well as a reduced overall survival (OS) (P = 0.016). Conclusions: The early-mid treatment serum CRP level is a prognostic factor in aggressive NHL. Patients who do not achieve an early-mid treatment level of <5 mg/L have quicker disease progression or earlier relapse and also appear to have an inferior OS.

Original languageEnglish
Pages (from-to)150-154
Number of pages5
JournalEuropean Journal of Haematology
Volume79
Issue number2
DOIs
StatePublished - Aug 2007
Externally publishedYes

Keywords

  • Aggressive non-Hodgkins lymphoma
  • C-reactive protein
  • Early-mid treatment
  • Prognostic factor

Fingerprint

Dive into the research topics of 'Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this